Literature DB >> 28689584

Hepatitis C Infection: A Systemic Disease

Zobair M Younossi1.   

Abstract

It is critical to recognize that hepatitis C virus (HCV) infection is, in fact, a multifaceted systemic disease with both hepatic and extrahepatic complications. It is also important to recognize that the comprehensive burden of HCV should include not only its clinical burden but also its burden on the economic and patient-reported outcomes. It is only through this comprehensive approach to HCV infection that we can fully appreciate its true burden and understand the full benefit of curing HCV for the patient and the society.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extrahepatic complications; Hepatic complications; Hepatitis C virus

Mesh:

Year:  2017        PMID: 28689584     DOI: 10.1016/j.cld.2017.03.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus.

Authors:  Sammy Saab; Timothy Ahn; Terina McDaniel; Beshoy Yanny; Myron J Tong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-08

2.  A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.

Authors:  Donna M Evon; Paul W Stewart; Jipcy Amador; Marina Serper; Anna S Lok; Richard K Sterling; Souvik Sarkar; Carol E Golin; Bryce B Reeve; David R Nelson; Nancy Reau; Joseph K Lim; K Rajender Reddy; Adrian M Di Bisceglie; Michael W Fried
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

3.  Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.

Authors:  Ying Yang; Feng-Ping Wu; Wen-Jun Wang; Juan-Juan Shi; Ya-Ping Li; Xin Zhang; Shuang-Suo Dang
Journal:  World J Gastroenterol       Date:  2019-11-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.